Advertisement

The Spectrum of Drug-Induced Interstitial Lung Disease

  • Ankush Ratwani
  • Bhavik Gupta
  • Brian W. Stephenson
  • Haresh Mani
  • A. Whitney BrownEmail author
Interstitial Lung Disease (A Hajari Case, Section Editor)
  • 4 Downloads
Part of the following topical collections:
  1. Topical Collection on Interstitial Lung Disease

Abstract

Purpose of Review

Drug-induced interstitial lung disease (DI-ILD) is a very challenging topic both clinically and academically. With the advent of new immunotherapy and ever-growing arsenal of chemotherapeutic and biologic agents for a variety of conditions, it is paramount for the clinician to assess for the development of pulmonary toxicity before irreversible lung damage occurs. In this review, we have summarized the literature and describe the most commonly implicated agents and also describe new and rare causes of DI-ILD.

Recent Findings

Bleomycin and amiodarone remain the most frequent culprits of DI-ILD. Proteasome inhibitors have been observed to cause pulmonary toxicity in some patients. GM-CSF has also emerged as a cause of DI-ILD in recent years. Nitrofurantoin is commonly associated with DI-ILD in the class of antimicrobial agents, with both acute and chronic toxicity described. Anti-TNF drugs, in particular, etanercept and infliximab, are the overwhelming offenders among the biologic agents. In addition, methotrexate has been widely associated with lung injury, especially in those with underlying rheumatoid arthritis.

Summary

Over 300 drugs are known to be associated with DI-ILD, and risk factors for the development of DI-ILD are not well understood. Radiographic patterns and histological patterns do not correlate well, and the data on treatment response to glucocorticoid therapy remains variable. Early identification, removal of the offending agent, and elimination of other causes of lung injury remain paramount in the approach to DI-ILD.

Keywords

Interstitial lung disease Drug-induced ILD DI-ILD Immunotherapy Chemotherapy 

Notes

Compliance with Ethical Standards

Conflict of Interest

Ankush Ratwani, Bhavik Gupta, Brian Stephenson, Haresh Mani, and A. Whitney Brown declare no conflicts of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Schwaiblmair M, Behr W, Haeckel T, Märkl B, Foerg W, Berghaus T. Drug induced interstitial lung disease. Open Respir Med J. 2012;6:63–74.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    • Matsuno O. Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res. 2012;13:39 A thorough review on the pathophysiologic mechanisms of DI-ILD including dose-dependent toxicity and immune-mediated injury. Further, it explores the potential of new diagnostic tests and highlights previously established diagnostics for evaluating DI-ILD. PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Müller NL, White DA, Jiang H, Gemma A. Diagnosis and management of drug-associated interstitial lung disease. Br J Cancer. 2004;91(Suppl 2):S24–30.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Yamada Y, Shiga T, Matsuda N, Hagiwara N, Kasanuki H. Incidence and predictors of pulmonary toxicity in Japanese patients receiving low-dose amiodarone. Circ J. 2007;71:1610–6.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Sovijärvi AR, Lemola M, Stenius B, Idänpään-Heikkilä J. Nitrofurantoin-induced acute, subacute and chronic pulmonary reactions. Scand J Respir Dis. 1977;58:41–50.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Akoun GM, Cadranel JL, Rosenow EC 3rd, Milleron BJ. Bronchoalveolar lavage cell data in drug-induced pneumonitis. Allerg Immunol. 1991;23:245–52.Google Scholar
  7. 7.
    Cleverley JR, Screaton NJ, Hiorns MP, Flint JDA, Müller NL. Drug-induced lung disease: high-resolution CT and histological findings. Clin Radiol. 2002;57:292–9.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Ellis SJ, Cleverley JR, Müller NL. Drug-induced lung disease: high-resolution CT findings. AJR Am J Roentgenol. 2000;175:1019–24.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Silva CIS, Müller NL. Drug-induced lung diseases: most common reaction patterns and corresponding high-resolution CT manifestations. Semin Ultrasound CT MR. 2006;27:111–6.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    • Conway R, Low C, Coughlan RJ, O’Donnell MJ, Carey JJ. Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled rrials: risk of lung disease in RA patients treated with MTX. Arthritis Rheumatol. 2014;66:803–12 This study was a large meta-analysis of 22 studies with 8584 participants showing a small but significant increase in the risk of lung disease in patients with RA treated with methotrexate compared with other disease-modifying antirheumatic drugs. PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Yuzurio S, Horita N, Shiota Y, Kanehiro A, Tanimoto M. Interstitial lung disease during trimethoprim/sulfamethoxazole administration. Acta Med Okayama. 2010;64:181–7.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Conte SC, Pagan V, Murer B. Bronchiolitis obliterans organizing pneumonia secondary to amiodarone: clinical, radiological and histological pattern. Monaldi Arch Chest Dis. 1997;52:24–6.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Oren S, Turkot S, Golzman B, London D, Ben-Dor D, Weiler Z. Amiodarone-induced bronchiolitis obliterans organizing pneumonia (BOOP). Respir Med. 1996;90:167–9.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Rossi SE, Erasmus JJ, McAdams HP, Sporn TA, Goodman PC. Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics. 2000;20:1245–59.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Gal AA. Drug and radiation toxicity. In: Dail and Hammer’s pulmonary pathology. In: Tomashefski JF, editor. Non-neoplastic lung disease, vol. 1. 3rd ed. New York: Springer Science + Business Media LLC; 2008. p. 807–27.Google Scholar
  16. 16.
    O’Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol. 2003;14:91–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Dana OA. Chemotherapy agents with known pulmonary side effects and their anesthetic and critical care implications. J Cardiothorac Vasc Anesth. 2017;31:2227–35.CrossRefGoogle Scholar
  18. 18.
    Mankikian J, Favelle O, Guillon A, Guilleminault L, Cormier B, Jonville-Béra AP, et al. Initial characteristics and outcome of hospitalized patients with amiodarone pulmonary toxicity. Respir Med. 2014;108:638–46.PubMedCrossRefGoogle Scholar
  19. 19.
    Twohig KJ, Matthay RA. Pulmonary effects of cytotoxic agents other than bleomycin. Clin Chest Med. 1990;11:31–54.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Danson S, Blackhall F, Hulse P, Ranson M. Interstitial lung disease in lung cancer: separating disease progression from treatment effects. Drug Saf. 2005;28:103–13.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Stamatoullas A, Brice P, Bouabdallah R, Mareschal S, Camus V, Rahal I, et al. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with frontline ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol. 2015;170:179–84.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Ingrassia TS 3rd, Ryu JH, Trastek VF, Rosenow EC 3rd. Oxygen-exacerbated bleomycin pulmonary toxicity. Mayo Clin Proc. 1991;66:173–8.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Johnson P, Federico M, Kirkwood A, Fosså A, Berkahn L, Carella A, et al. Adapted treatment guided by Interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med. 2016;374:2419–29.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Yoshizawa K, Mukai HY, Miyazawa M, Miyao M, Ogawa Y, Ohyashiki K, et al. Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: incidence, mortality and clinical characterization. Cancer Sci. 2014;105:195–201.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Lim K-H, Chang Y-H. Interstitial lung disease and gefitinib. N Engl J Med. 2010;363:1579 author reply 1579–80.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Minegishi Y, Maemondo M, Okinaga S, Morikawa N, Inoue A, Kobayashi K, et al. First-line gefitinib therapy for elder advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: Multicenter phase II trial (NEJ 003 study). J Clin Orthod. Proc Am Soc Clin Oncol; 2010;28:7561–7561.Google Scholar
  27. 27.
    Adachi K, Suzuki M, Sugimoto T, Yorozu K, Takai H, Uetsuka K, et al. Effects of granulocyte colony-stimulating factor (G-CSF) on bleomycin-induced lung injury of varying severity. Toxicol Pathol. 2003;31:665–73.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Yokose N, Ogata K, Tamura H, An E, Nakamura K, Kamikubo K, et al. Pulmonary toxicity after granulocyte colony-stimulating factor-combined chemotherapy for non-Hodgkin’s lymphoma. Br J Cancer. 1998;77:2286–90.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Stephenson BW, Swierzbinski MJ, Ahmad K, Shlobin OA, Brown AW, Aryal S, et al. Filgrastim-induced acute respiratory distress syndrome. C42 Critical Care Case Reports: Toxicology and Poisonings 2. Am Thorac Soc. 2019:A4851–1.Google Scholar
  30. 30.
    Mendez JL, Nadrous HF, Hartman TE, Ryu JH. Chronic nitrofurantoin-induced lung disease. Mayo Clin Proc. 2005;80:1298–302.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Durante-Mangoni E, Andini R, Parrella A, Mattucci I, Cavezza G, Senese A, et al. Safety of treatment with high-dose daptomycin in 102 patients with infective endocarditis. Int J Antimicrob Agents. 2016;48:61–8.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Papiris SA, Triantafillidou C, Kolilekas L, Markoulaki D, Manali ED. Review of pulmonary effects and toxicity. Drug Saf. 2010;33:539–58.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Wolkove N, Baltzan M. Amiodarone pulmonary toxicity. Can Respir J. 2009;16:43–8.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Polverosi R, Zanellato E, Doroldi C. Thoracic radiography and high resolution computerized tomography in the diagnosis of pulmonary disorders caused by amiodarone. Radiol Med. 1996;92:58–62.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Ernawati DK, Stafford L, Hughes JD. Amiodarone-induced pulmonary toxicity. Br J Clin Pharmacol. 2008;66:82–7.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Khabbaza JE, Bauer SR, Reddy AJ. Incidence of pulmonary toxicity after initiation of dronedarone: a cross-sectional study. Am J Respir Crit Care Med. 2014;189:A1506.Google Scholar
  37. 37.
    Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, Pego-Reigosa JM, Retamozo S, Bove A, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum. 2011;41:256–64.PubMedCrossRefGoogle Scholar
  38. 38.
    Peerzada MM, Spiro TP, Daw HA. Pulmonary toxicities of biologics: a review. Anti-Cancer Drugs. 2010;21:131–9.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Bienvenu J, Chvetzoff R, Salles G, Balter C, Tilly H, Herbrecht R, et al. Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. Hematol J. 2001;2:378–84.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Naqibullah M, Shaker SB, Bach KS, Bendstrup E. Rituximab-induced interstitial lung disease: five case reports. Eur Respir J. 2015;2. Available from:  https://doi.org/10.3402/ecrj.v2.27178
  41. 41.
    Sugaya A, Ishiguro S, Mitsuhashi S, Abe M, Hashimoto I, Kaburagi T, et al. Interstitial lung disease associated with trastuzumab monotherapy: a report of 3 cases. Mol Clin Oncol. 2017;6:229–32.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    •• Skeoch S, Weatherley N, Swift AJ, Oldroyd A, Johns C, Hayton C, et al. Drug-induced interstitial lung disease: a systematic review. J Clin Med Res. 2018;7. Available from:  https://doi.org/10.3390/jcm7100356. A large PRISMA-compliant systematic review of 156 full-text papers highlighting the prevalence, drug frequency, radio-pathological phenotypes, prognosis, and treatment options for DI-ILD.
  43. 43.
    Imokawa S, Colby TV, Leslie KO, Helmers RA. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J. 2000;15:373–81.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Jakubovic BD, Donovan A, Webster PM, Shear NH. Methotrexate-induced pulmonary toxicity. Can Respir J. 2013;20:153–5.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Camus P, Degat OR, Justrabo E, Jeannin L. D-Penicillamine-induced severe pneumonitis. Chest. 1982;81:376–8.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Pawadshettar S, Acharya VK, Arun M, Unnikrishnan B, Tantry BV. Penicillamine in interstitial lung disease: a timely remainder of an old foe. Asian J Pharm Clin Res. 2016;9:351–3.Google Scholar
  47. 47.
    Ganguli A, Pirmohamed M. Management of drug-induced interstitial lung disease. Prescriber. 2006;17:41–6.CrossRefGoogle Scholar
  48. 48.
    Diane Goodwin S, Glenny RW. Nonsteroidal anti-inflammatory drug—associated pulmonary infiltrates with eosinophilia: review of the literature and Food and Drug Administration adverse drug reaction reports. Arch Intern Med. 1992;152:1521–4.CrossRefGoogle Scholar
  49. 49.
    Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol. 1998;16:1287–93.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Ohnishi H, Yokoyama A, Kondo K, Hamada H, Abe M, Nishimura K, et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med. 2002;165:378–81.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Ankush Ratwani
    • 1
  • Bhavik Gupta
    • 1
  • Brian W. Stephenson
    • 2
  • Haresh Mani
    • 3
  • A. Whitney Brown
    • 4
    Email author
  1. 1.Department of Internal MedicineMedStar Georgetown University HospitalWashingtonUSA
  2. 2.Department of MedicineDuke Medical CenterDurhamUSA
  3. 3.Department of PathologyInova Fairfax HospitalFalls ChurchUSA
  4. 4.Inova Advanced Lung Disease and Transplant ProgramInova Fairfax HospitalFalls ChurchUSA

Personalised recommendations